A61P 19 - Drugs for skeletal disorders

Patents for A61P 19 - Drugs for skeletal disorders (81,981)
12/2001
12/18/2001	US6331433 Human T cell leukemia cell line designated D1.1
12/18/2001	US6331410 Polynucleotides encoding a novel pyrR homolog
12/18/2001	CA2202484C Use of indole derivatives for the treatment of various diseases
12/18/2001	CA2178161C Indole derivatives
12/13/2001	WO2001094612A2 Method for identifying medically valuable active substances
12/13/2001	WO2001094585A1 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof
12/13/2001	WO2001094555A1 Method for obtaining characterised muscle-derived cell populations and uses
12/13/2001	WO2001094415A2 Nuclear hormone receptor
12/13/2001	WO2001094413A2 B7-related nucleic acids and polypeptides and their uses for immunomodulation
12/13/2001	WO2001094391A2 Intracellular signaling proteins
12/13/2001	WO2001094381A2 Novel compounds of the n-acylamino-amide family, compositions comprising same, and uses
12/13/2001	WO2001094368A1 2-aminocarbonyl-9h-purine derivatives
12/13/2001	WO2001094351A1 Caspase inhibitors and uses thereof
12/13/2001	WO2001094347A1 Tetracyclic diketopiperazine compounds as pdev inhibitors
12/13/2001	WO2001094345A2 Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
12/13/2001	WO2001094338A1 Admantane derivatives
12/13/2001	WO2001094325A1 2-aminothiazoline derivatives and their use as no-synthase inhibitors
12/13/2001	WO2001094312A2 Indolinone derivatives as protein kinase/phosphatase inhibitors
12/13/2001	WO2001094293A2 Benzamide ligands for the thyroid receptor
12/13/2001	WO2001093983A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same
12/13/2001	WO2001093911A2 Macromolecular drug complexes and compositions containing the same
12/13/2001	WO2001093885A1 Therapeutic agents - ii
12/13/2001	WO2001093884A1 Therapeutic agents - i
12/13/2001	WO2001093883A1 Therapeutic agents - iii
12/13/2001	WO2001093882A1 Purified material having size and growth inhibitory effects on cells and tissues
12/13/2001	WO2001093867A1 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-synthase inhibitors
12/13/2001	WO2001093847A2 Compositions, kits, and methods for promoting defined health benefits
12/13/2001	WO2001093833A2 Kits and methods for optimizing the efficacy of chondroprotective compositions
12/13/2001	WO2001093831A2 Low carbohydrate compositions, kits thereof, and methods of use
12/13/2001	WO2001093701A2 Aqueous chondroprotective compositions having defined ph limitations for efficacious delivery
12/13/2001	WO2001044445A3 Human lyases and associated proteins
12/13/2001	WO2001044200A3 Selective neurokinin antagonists
12/13/2001	WO2001037820A3 Ionizable indolinone derivatives and their use as ptk ligands
12/13/2001	WO2001026682A3 Modified plant viruses and methods of use thereof
12/13/2001	WO2001021008A3 Method for increasing pet activity
12/13/2001	WO2000044888A3 Dimethylarginine dimethylaminohydrolases
12/13/2001	WO2000032773A9 Compositions and methods for increasing bone mineralization
12/13/2001	US20010051646 Method for the improvement of islet signaling in diabetes mellitus and for its prevention
12/13/2001	US20010051636 Combination treatment for inhibiting bone loss
12/13/2001	US20010051619 E.g., ethyl 3-(4-(2-(3-oxo-2H-1,4-benzoxazin-4-yl)ethoxy)-phenyl-2-ethoxypropenoate where 1,4-benzothiazine or quinoxaline can be substituted for the benzoxazine ring; anticholesterol, diabetic agents; obesity; hyperlimpidemia
12/13/2001	US20010051616 Administering alendronate sodium
12/13/2001	EP1143806A3 Method for increasing pet activity
12/13/2001	DE10101324C1 New 1-(dimercaptoalkyl)-quinazoline-2,4(1H,3H)-diones, are stable matrix metalloproteinase inhibitors useful e.g. for treating rheumatism, tumor metastasis or sunburn
12/13/2001	DE10025609A1 Transfektionssystem Transfection
12/13/2001	CA2707766A1 Plasmids ptqomp and ptto-1 which have an ompa signal sequence
12/13/2001	CA2412377A1 B7-related nucleic acids and polypeptides and their uses for immunomodulation
12/13/2001	CA2411762A1 Method for obtaining characterised muscle-derived cell populations and uses
12/13/2001	CA2411596A1 Therapeutic agents - ii
12/13/2001	CA2411062A1 Benzamide ligands for the thyroid receptor
12/13/2001	CA2411010A1 Tetracyclic diketopiperazine compounds as pdev inhibitors
12/13/2001	CA2410509A1 Indolinone derivatives as protein kinase/phosphatase inhibitors
12/13/2001	CA2409392A1 Intracellular signaling proteins
12/13/2001	CA2409268A1 Macromolecular drug complexes and compositions containing the same
12/13/2001	CA2409015A1 Caspase inhibitors and uses thereof
12/13/2001	CA2408748A1 Nuclear hormone receptor
12/13/2001	CA2408670A1 Novel compounds of the n-acylamino-amide family, compositions comprising same, and uses
12/13/2001	CA2408612A1 Aqueous chondroprotective compositions having defined ph limitations for efficacious delivery
12/13/2001	CA2408611A1 Kits and methods for optimizing the efficacy of chondroprotective compositions
12/13/2001	CA2408610A1 Low carbohydrate compositions, kits thereof, and methods of use
12/13/2001	CA2408609A1 Compositions, kits, and methods for promoting defined health benefits
12/12/2001	EP1161944A1 Drugs, foods and oral compositions containing stilbene-type compounds
12/12/2001	EP1161549A2 Retrovirus producing cells utilizing a high multiplicity of transduction
12/12/2001	EP1161450A1 Bone stimulating factor
12/12/2001	EP1161447A1 50 human secreted proteins
12/12/2001	EP1161444A1 A novel inhibitor of programmed cell death
12/12/2001	EP1161433A1 Tyrosine kinase inhibitors
12/12/2001	EP1161429A2 Heterocyclic compounds as adenosine deaminase inhibitors
12/12/2001	EP1161422A1 Amine derivatives as protease inhibitors
12/12/2001	EP1161419A1 Spirocyclic ketones and their use as tachykinin antagonists
12/12/2001	EP1161415A2 N-cyanomethylamides as protease inhibitors
12/12/2001	EP1161412A1 Nuclear receptor arylating compounds
12/12/2001	EP1161410A1 Retinoid antagonists and use thereof
12/12/2001	EP1161280A1 Use of an integrin antagonist and a chemotherapeutic agent in the treatment of neoplasia
12/12/2001	EP1161261A1 Apoptosis inducing molecule ii and methods of use
12/12/2001	EP1161258A1 Compositions and methods of use of ldl-like receptor ligands for the treatment of cancer and angiogenic-based disease
12/12/2001	EP1161257A2 Pharmaceutical compositions comprising tgf-beta
12/12/2001	EP1161237A1 Protease inhibitors
12/12/2001	EP1161235A1 Combinations for the treatment of diseases involving angiogenesis
12/12/2001	EP1161233A2 Lxr modulators
12/12/2001	EP1161232A1 Hydroxy diphenyl urea sulfonamides as il-8 receptor antagonists
12/12/2001	EP0938471B1 The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
12/12/2001	EP0772597B1 3,4-substituted pyrazoles for the treatment of inflammation
12/12/2001	EP0662075B1 Prostaglandin analog for treating osteoporosis
12/12/2001	CN1326457A 4-aminopyrrolopyrimidines as kinase inhibitors
12/12/2001	CN1326449A Chrystals of 5-[{6-(2-fluorobenzyl)oxy-2-naphthyl}methyl]-2, 4-thiazolidinedione
12/12/2001	CN1326443A Fluorinated 3,4-dihydroquinoline derivatives used as NOS inhibitors
12/12/2001	CN1326361A Methods for detecting, preventing, and treating renal disorders by modulating, regulating and inhibiting connective tissue growth factor
12/12/2001	CN1326344A PUFA supplements
12/12/2001	CN1326338A Process for preparing oral calcium compositions
12/12/2001	CN1325726A Guling ointment
12/12/2001	CN1325713A Process for preparing Chinese medicine 'Gubao' to treat osteopathy
12/12/2001	CN1325700A Liniment for treating hyperosteogeny
12/12/2001	CN1325684A Application of aminoguanidine in preparing medicine to treat hyperosteogeny
12/12/2001	CN1075948C External-used medicine for treating protrusion of intervertebral disc
12/11/2001	US6329526 Cycloalkyl substituted imidazoles
12/11/2001	US6329418 Substituted pyrrolidine hydroxamate metalloprotease inhibitors
12/11/2001	US6329415 Aromatic heterocyclic compounds as antiinflammatory agents
12/11/2001	US6329397 Hydroxy pipecolate hydroxamic acid derivatives
12/11/2001	US6329385 Antiinflammatory agents, antiarthritic agents, viral diseases and gastrointestinal disorders
12/11/2001	US6329380 Pyrimidine benzimidizazole, pyrimidineimidazole or pyridine imidazole compounds for anticancer agents or atherosclerosis

1 ... 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 ... 820